Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 44

1.

Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis.

Chitnis T, Arnold DL, Banwell B, Brück W, Ghezzi A, Giovannoni G, Greenberg B, Krupp L, Rostásy K, Tardieu M, Waubant E, Wolinsky JS, Bar-Or A, Stites T, Chen Y, Putzki N, Merschhemke M, Gärtner J; PARADIGMS Study Group.

N Engl J Med. 2018 Sep 13;379(11):1017-1027. doi: 10.1056/NEJMoa1800149.

PMID:
30207920
2.

[Provision of alemtuzumab safety is one of the main components of pharmacovigilance].

Khachanova NV, Bakhtiyarova KZ, Boyko AN, Vlasov YV, Davydovskaia MV, Evdoshenko EP, Zakharova MN, Malkova NA, Sivertseva SA, Spirin NN, Stolyarov ID, Schmidt TE, Khabirov FA.

Zh Nevrol Psikhiatr Im S S Korsakova. 2018;118(8. Vyp. 2):82-87. doi: 10.17116/jnevro201811808282. Russian.

PMID:
30160673
3.

[The results of an open comparative retrospective trial of the course of multiple sclerosis during treatment with infibeta and other interferon-beta bioanalogues and glatiramer acetate].

Khabirov FA, Khaybullin TI, Granatov EV, Shakirzianova SR, Babicheva NN, Kochergina OS, Rakhmatullina EF, Akhmedova GM, Averyanova LA, Yakupov MA, Sabirov ZF.

Zh Nevrol Psikhiatr Im S S Korsakova. 2018;118(3):18-26. doi: 10.17116/jnevro20181183118-26. Russian.

PMID:
29652301
4.

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study.

Kappos L, Bar-Or A, Cree BAC, Fox RJ, Giovannoni G, Gold R, Vermersch P, Arnold DL, Arnould S, Scherz T, Wolf C, Wallström E, Dahlke F; EXPAND Clinical Investigators.

Lancet. 2018 Mar 31;391(10127):1263-1273. doi: 10.1016/S0140-6736(18)30475-6. Epub 2018 Mar 23.

PMID:
29576505
5.

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.

Kapoor R, Ho PR, Campbell N, Chang I, Deykin A, Forrestal F, Lucas N, Yu B, Arnold DL, Freedman MS, Goldman MD, Hartung HP, Havrdová EK, Jeffery D, Miller A, Sellebjerg F, Cadavid D, Mikol D, Steiner D; ASCEND investigators.

Lancet Neurol. 2018 May;17(5):405-415. doi: 10.1016/S1474-4422(18)30069-3. Epub 2018 Mar 12.

PMID:
29545067
6.

Effects of ATX-MS-1467 immunotherapy over 16 weeks in relapsing multiple sclerosis.

Chataway J, Martin K, Barrell K, Sharrack B, Stolt P, Wraith DC; ATX-MS1467 Study Group.

Neurology. 2018 Mar 13;90(11):e955-e962. doi: 10.1212/WNL.0000000000005118. Epub 2018 Feb 21.

PMID:
29467307
7.

[Primary progressive multiple sclerosis: current issues of timely diagnosis].

Popova EV, Boyko AN, Barabanova MA, Antipova LN, Bakhtiyarova KZ, Belova AN, Solovieva VS, Belskaya GN, Lukashevich IG, Nikolaeva LI, Volkova LI, Turova EL, Kraeva AV, Goncharova ZA, Malkova NA, Poverennova IE, Sivertseva SA, Zhelnin AV, Trushnikova TN, Khabirov FA, Khaibullin TI.

Zh Nevrol Psikhiatr Im S S Korsakova. 2017;117(10. Vyp. 2):35-40. doi: 10.17116/jnevro201711710235-40. Russian.

PMID:
29359731
8.

[Evaluation of efficiency and safety of adding neuromultivit to basic therapy of vertebrogenic radiculopathy].

Khabirov FA, Khaibullin TI, Granatov EV.

Zh Nevrol Psikhiatr Im S S Korsakova. 2017;117(10):38-43. doi: 10.17116/jnevro201711710138-43. Russian.

PMID:
29171487
9.

Divergent Immunomodulation Capacity of Individual Myelin Peptides-Components of Liposomal Therapeutic against Multiple Sclerosis.

Ivanova VV, Khaiboullina SF, Gomzikova MO, Martynova EV, Ferreira AM, Garanina EE, Sakhapov DI, Lomakin YA, Khaibullin TI, Granatov EV, Khabirov FA, Rizvanov AA, Gabibov A, Belogurov A Jr.

Front Immunol. 2017 Oct 16;8:1335. doi: 10.3389/fimmu.2017.01335. eCollection 2017.

10.

[A comparative placebo-controlled clinical study on the efficacy and safety of interferon beta-1a for subcutaneous injections in patients with remitting multiple sclerosis: results of the first year of observations].

Boyko AN, Bosenko LP, Vasilovskiy VV, Volkova LI, Zakharova MN, Kotov SV, Lekomtseva EV, Negrich TI, Parshina EV, Patrusheva OP, Prokopenko SV, Sazonov DV, Timchenko PV, Trinitatskiy YV, Khabirov FA, Khavunka MY, Chichanovskaya LV, Sherman MA, Lin'kova YN, Zinkina-Orikhan AV, Tursunova KB.

Zh Nevrol Psikhiatr Im S S Korsakova. 2017;117(2. Vyp. 2):107-113. doi: 10.17116/jnevro201711722107-113. Russian.

PMID:
28617368
11.

Elevated Levels of Proinflammatory Cytokines in Cerebrospinal Fluid of Multiple Sclerosis Patients.

Khaibullin T, Ivanova V, Martynova E, Cherepnev G, Khabirov F, Granatov E, Rizvanov A, Khaiboullina S.

Front Immunol. 2017 May 18;8:531. doi: 10.3389/fimmu.2017.00531. eCollection 2017.

12.

[Effect of cerebrolysin on remyelination processes in multiple sclerosis patients in stage of relapse regression].

Khabirov FA, Khaybullin TI, Granatov EV, Shakirzianova SR.

Zh Nevrol Psikhiatr Im S S Korsakova. 2016;116(12):48-53. doi: 10.17116/jnevro201611612148-53. Russian.

PMID:
28139626
13.

[Clinical recommendations on the use of teriflunomide].

Alifirova VM, Bakhtiyarova KZ, Belova AN, Bisaga GN, Boiko AN, Boiko OV, Vlasov YV, Volkova LI, Goncharova ZA, Davydovskaya MV, Zakharova MN, Kotov SV, Lashch NY, Malkova NA, Petrov AM, Popova EV, Sivertseva SA, Sokolova IA, Spirin NN, Stolyarov ID, Streknev AG, Totolyan NA, Khachanova NV, Sherman MI, Shmidt TE, Khabirov FA, Yampol'skaya-Gosteva IA.

Zh Nevrol Psikhiatr Im S S Korsakova. 2016;116(10 Pt 2):98-104. doi: 10.17116/jnevro201611610298-104. Russian. No abstract available.

PMID:
28139617
14.

[Comparative, placebo-controlled clinical study of efficacy and safety of glatiramer acetate 20 mg in patients with relapsing-remitting multiple sclerosis: results of the first year of the study].

Boyko AN, Lashch NY, Sharanova SN, Zakharova MN, Trifonova OV, Simaniv TO, Lysogorskaya EV, Guryanova OE, Kotov SV, Iakushina TI, Lizhdvoy VY, Belova YA, Khabirov FA, Babicheva NN, Khaibullin TI, Granatov EV, Averyanova LA, Sazonov DV, Odinak MM, Trinitatsky YV, Tsukurova LA, Sergeeva AI, Ivanov RA, Shustova MS.

Zh Nevrol Psikhiatr Im S S Korsakova. 2016;116(10 Pt 2):61-67. doi: 10.17116/jnevro201611610261-67. Russian.

PMID:
28139613
15.

[Clinical, neurophysiological and neuroimaging study of tremor in multiple sclerosis].

Khabirov FA, Averianova LA, Babicheva NN, Granatov EV, Khaybullin TI.

Zh Nevrol Psikhiatr Im S S Korsakova. 2015;115(2 Pt 2):21-30. doi: 10.17116/jnevro20151152221-30. Russian.

PMID:
26081333
16.

[The results of the multicenter pharmaco-epidemiological observational project on the use of mydocalm in the treatment of pain syndromes with the muscle spasm].

Skoromets AA, Guekht AB, Galanov DV, Danilenko OA, Barantsevich ER, Lebedeva AV, Belova AN, Shprakh VV, Bogdanov EI, Prokopenko SV, Khabirov FA, Spirin NN, Baliazin VA, Miakotnykh VS, Volkova LI, Gafurov BG, Mishchenko TS, Toktomushev CT, Shyralieva RK, Musaev SK, Guseinov SG.

Zh Nevrol Psikhiatr Im S S Korsakova. 2015;115(12):104-109. doi: 10.17116/jnevro2015115112104-109. Russian.

PMID:
26978502
17.

Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.

Calabresi PA, Kieseier BC, Arnold DL, Balcer LJ, Boyko A, Pelletier J, Liu S, Zhu Y, Seddighzadeh A, Hung S, Deykin A; ADVANCE Study Investigators.

Lancet Neurol. 2014 Jul;13(7):657-65. doi: 10.1016/S1474-4422(14)70068-7. Epub 2014 Apr 30.

PMID:
24794721
18.

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial.

Giovannoni G, Gold R, Selmaj K, Havrdova E, Montalban X, Radue EW, Stefoski D, McNeill M, Amaravadi L, Sweetser M, Elkins J, O'Neill G; SELECTION Study Investigators.

Lancet Neurol. 2014 May;13(5):472-81. doi: 10.1016/S1474-4422(14)70039-0. Epub 2014 Mar 19.

PMID:
24656609
19.

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial.

Gold R, Giovannoni G, Selmaj K, Havrdova E, Montalban X, Radue EW, Stefoski D, Robinson R, Riester K, Rana J, Elkins J, O'Neill G; SELECT study investigators.

Lancet. 2013 Jun 22;381(9884):2167-75. doi: 10.1016/S0140-6736(12)62190-4. Epub 2013 Apr 4.

PMID:
23562009
20.

[Biosimilar of interferon-beta 1b in the treatment of multiple sclerosis and the own experience in the use of ronbetal].

Khabirov FA, Babicheva NN, Khaĭbullin TI, Aver'ianova LA, Granatov EV, Akhmedova GM.

Zh Nevrol Psikhiatr Im S S Korsakova. 2012;112(9 Pt 2):113-22. Review. Russian.

PMID:
23235429

Supplemental Content

Loading ...
Support Center